OBJECTIVE To evaluate the cost-effectiveness of PEG-rhG-CSF versus rhG-CSF in patients with epithelial ovarian cancer in central China for preventing chemotherapy-induced neutropenia. METHODS Two Markov models form healthcare system perspective were developed to evaluate the economics of PEG-rhG-CSF versus rhG-CSF using cost-utility analysis. Cost and probability input data were primarily obtained from a retrospective real-world study conducted in four tertiary hospitals from January 2019 to December 2020. One-way sensitivity analysis,probability sensitivity analysis and scenario analysis were used to verify the robustness of the results. RESULTS The basic analysis showed that, compared with rhG-CSF, PEG-rhG-CSF resulted in higher QALYs and lower cost, gained 0.27 QALYs more while spending 2279.63 yuan less, and the incremental cost-effectiveness ratios were ¥-8393.9/QALY. Sensitivity analysis and scenario analysis revealed robust results. CONCLUSION PEG-rhG-CSF is economically advantageous in Chinese patients with epithelial ovarian cancer for preventing chemotherapy-induced neutropenia.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |